Maria A. Ceregido

Waver, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trial.

Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trial.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: July 30, 2025

Adjuvant system AS01: from mode of action to effective vaccines.

Adjuvant system AS01: from mode of action to effective vaccines.

Journal: Expert review of vaccines

Published: July 23, 2024

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.

Journal: EClinicalMedicine

Published: May 24, 2023

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.

Journal: The Lancet. Respiratory medicine

Published: April 19, 2023

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

Journal: EClinicalMedicine

Published: April 11, 2023

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.

Journal: medRxiv : the preprint server for health sciences

Published: December 16, 2022

Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies.

Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies.

Journal: Infectious diseases and therapy

Published: July 22, 2022

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.

Journal: EClinicalMedicine

Published: March 21, 2022

Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.

Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.

Journal: Vaccine

Published: November 19, 2021

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.

Journal: NPJ vaccines

Published: November 14, 2021

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.

Journal: Nature communications

Published: October 28, 2021

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.

Journal: The Lancet. Infectious diseases

Published: October 08, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026